This article provides an overview of the current knowledge regarding diagnostic imaging of
patients with soft-tissue sarcomas, which is a heterogeneous group of rare mesenchymal …

Sarcoma subtype classification is currently mainly based upon histopathological
morphology. Molecular analyses have emerged as an efficient addition to the diagnostic …

We designed a liquid biopsy (LB) platform employing low-pass whole genome sequencing
(LP-WGS) and targeted sequencing of cell-free (cf) DNA from plasma to detect genome-wide …

Background The tumor microenvironment (TME) has a central role in the oncogenesis of
osteosarcomas. The composition of the TME is essential for the interaction between tumor …

Brigimadlin (BI 907828) is an oral MDM2–p53 antagonist that has shown encouraging
antitumor activity in vivo. We present phase Ia results from an open-label, first-in-human …

Purpose: Developing new therapeutics for any of the more than 100 sarcoma subtypes
presents a challenge. After progression from standard therapies, patients with sarcoma may …

Myxofibrosarcoma (MFS) and undifferentiated pleomorphic sarcoma (UPS) can be
considered as a spectrum of the same disease entity, representing one of the most common …

Objective The objective was to review the pharmacology, efficacy, and safety of
atezolizumab (Tecentriq) for the treatment of adult and pediatric patients aged 2 years and …

Liposarcoma is the most commonly occurring soft-tissue sarcoma and is frequently
characterized by amplification of chromosome region 12q13–15 harboring the oncogenes …

Murine double minute 2 (MDM2) inhibitors represent an opportunity to target p53 in solid
tumors with wild-type TP53 and particularly in some sarcomas characterized by a consistent …